Condition: Healthy · Sponsor: RemeGen Co., Ltd.
This is an open-label, randomized, parallel group, single dose study in healthy Chinese subjects. The purpose of this study is to evaluate the Pharmacokinetics and safety of Telitacicept Pre-filled Injection and Freeze-dried powder Injection.
This description comes directly from the study's public registry record.
Binghua Xiao · 86-010-58076833 · binghua.xiao@remegen.com
Always discuss trial participation with your own doctor first.
| The Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Tianjin People's Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06549959